Kido Y, Tamai I, Ohnari A, et al
doi: 10.1016/j.celrep.2017.07.055
Her doctor explained that her exposure during weeks 3-4 fell in that early transition period
GLP-1s have quickly shifted from a niche diabetes therapy to a broad-reaching class of medications with the potential to transform chronic disease management, said Dr
However, most studies of pancreatic mass or exocrine cellular proliferation have reported no change with exenatide, liraglutide, or dulaglutide (86, 108, 109, 119, 121)
While short-acting versions like daily injections may better control postprandial glucose levels, they have largely been replaced by long-acting alternatives such as semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound), which only require weekly injections